Clinical effects of restarting antiplatelet therapy in patients with intracerebral hemorrhage

Abstract

Objective: Antiplatelet (APT) medications have been used to treat ischemic stroke and cardiovascular diseases. However, they involve a risk of re-bleeding, especially in patients with intracerebral hemorrhage (ICH), which limits their clinical application. This study aimed to compare the incidence of recurrent ICH and ischemic events in ICH survivors on APT, as well as to assess the clinical effect and safety of APT resumption.

Methods: We retrospectively reviewed the medical records of patients with spontaneous ICH at two tertiary medical centers between January 2011 and December 2020. We included adult patients with ICH who regularly took APT medications for various medical conditions. The patients were divided into two groups based on their APT resumption. Subsequently, we performed between-group comparisons of clinical or radiological characteristics; moreover, analyzed the incidence of re-bleeding and ischemic events, as well as the various risk factors for each event.

Results: We included 202 patients; among them, 118 patients restarted APT after initial ICH (APT resumption group) while 84 patients did not (no-APT resumption group). Compared with patients in the no-APT resumption group, those in the APT resumption group were more likely to have hyperlipidemia (p < 0.001) and a previous ischemic stroke event (p = 0.026). Recurrent ICH and ischemic vascular events occurred in 14 and 15 patients, respectively. Univariate analysis demonstrated that the risk factors for recurrent ICH were older age, renal dysfunction, and no APT resumption; however, only renal dysfunction significantly increased the risk of re-bleeding in multivariate analysis (HR, 4.631; 95 % CI 1.432-14.977; p = 0.010). Moreover, previous cerebral ischemia and atrial fibrillation were positively associated with ischemic events in univariate analysis; however, only atrial fibrillation demonstrated a significant correlation in multivariate analysis (HR, 4.309; 95 % CI 1.383-13.426; p = 0.012). APT resumption had a significant prevention effect on recurrent ICH (HR, 0.180; 95 % CI 0.055-0.586; p = 0.004) and ischemic vascular events (HR, 0.240; 95 % CI 0.077-0.750; p = 0.014).

Conclusions: Our findings indicated that restarting APT in patients with ICH was not associated with an increased risk of recurrent ICH. APT can be safely restarted to prevent major thromboembolic complications in patients on previous antithrombotic treatment.